The library
Every page, one ledger.
11 pages
01
Drugs & Trials
Reading a Clinical Trial: Phase I to Phase III in Plain Words
What each phase asks, what a placebo group does, and which words in a press release deserve suspicion.
02
Drugs & Trials
Venom to Medicine: Drugs Born From Animal Toxins
A pit viper, a lizard, a cone snail and a leech each handed pharmacology a peptide blueprint. Four true stories of toxins turned into treatments.
03
Drugs & Trials
Why Most Peptides Can't Be Swallowed
The digestive system is designed to take peptides apart. Here is how the few oral peptide drugs get past it, and why injections still dominate.
04
Drugs & Trials
AOD 9604 Dosage Chart With Calculator Notes From Each Study
Each AOD-9604 study used its own route, species and endpoint, so none of its figures transfers. A calculator gives solution strength only, never a dose.
05
Drugs & Trials
Cagrilintide Dosage Reference From Amylin Research
A reference on amylin biology, the pramlintide label and the trials that tested cagrilintide on its own, including the RENEW phase 3 programme started in 2025.
06
Drugs & Trials
CJC 1295 Ipamorelin Dosage Protocol and What the Studies Measured
A field note on the amounts, intervals and routes that human studies of CJC-1295 and ipamorelin actually used, and why combined daily charts have no established basis.
07
Drugs & Trials
Does Tesamorelin Cause Cancer or Other Long Term Problems
What the Egrifta label says about neoplasms and IGF-1, what its one year trials could and could not show, and which long term safety questions remain open.
08
Drugs & Trials
Eloralintide Peptide Guide for Beginners in Amylin Research
A plain guide to Lilly's selective amylin agonist eloralintide: how it differs from cagrilintide, what phase 1 and phase 2 trials found and where phase 3 stands.
09
Drugs & Trials
Ipamorelin Dosage per Day and the Trial Protocols Behind It
How ipamorelin went from a selective secretagogue in animal tests to volunteer infusions and a bowel surgery trial, and why no daily human dose has been established.
10
Drugs & Trials
Mazdutide vs Retatrutide Comparison of Two Glucagon Based Peptides
How the dual agonist mazdutide and the triple agonist retatrutide differ in design, trial results and approval status, and why no head to head data exist yet.